Research programme: sarcoplasmic reticulum calcium transporting ATPase 2b isoform modulators - Celladon

Drug Profile

Research programme: sarcoplasmic reticulum calcium transporting ATPase 2b isoform modulators - Celladon

Latest Information Update: 07 Aug 2015

Price : $50

At a glance

  • Originator Celladon
  • Class Small molecules
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Diabetes mellitus; Neurodegenerative disorders

Most Recent Events

  • 07 Aug 2015 Research programme: sarcoplasmic reticulum calcium transporting ATPase 2b isoform modulators - Celladon is available for licensing as of 26 Jun 2015. www.celladon.com
  • 26 Jun 2015 Suspended - Preclinical for Neurodegenerative disorders in USA (unspecified route)
  • 26 Jun 2015 Suspended - Preclinical for Diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top